ArticleInternational journal of surgery protocols2025
Clinical trial evaluating the efficacy and safety of percutaneous prostate cancer lesion-targeted microwave tissue coagulation for prostate functional preservation: MicroPro2.
Article in International journal of surgery protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Focal therapy (FT) for localized prostate cancer (PC) aims to achieve cancer control and maintain quality of life. Microwave tissue coagulation (MTC) is a tissue-coagulation thermotherapy that has been used to treat solid tumors such as kidney, liver, and lung tumors. However, the use of this technology in lesion-targeted FT for PC has not been established. Methods: We will perform a prospective multi-center, single-arm, clinical study to evaluate the efficacy and safety of lesion-targeted focal MTC for localized PC. In eight centers with expert urologists for performing magnetic resonance imaging (MRI)/ultrasound (US) fusion biopsy, patients will be evaluated prospectively after lesion-targeted MTC. The target sample size is 65. This study was registered with the Japan Registry of Clinical Trials and ClinicalTrials.gov. Inclusion criteria were patients who had a single MRI-visible lesion with Prostate Imaging Reporting and Data System (PI-RADS) category 3 or 4 that was proven as Gleason score of 7 or 8 cancer by enrollment biopsy or patients who had a single MRI-visible lesion with PI-RADS category 4 or 5 that was proven as Gleason score of 6 or 7 by enrollment biopsy. The primary endpoint is the disappearance of the targeted cancer lesion at 6 months after microwave coagulation, evaluated by a combined response in prostate-specific antigen, MRI, and prostate biopsy. Discussion: The importance of this clinical trial is to establish a new ablative treatment option for lesion-targeted FT in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.